Diffusion Pharmaceuticals (NASDAQ:DFFN) posted its quarterly earnings results on Thursday. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.06, Bloomberg Earnings reports.
NASDAQ DFFN traded down $0.02 on Friday, hitting $2.15. 50,401 shares of the stock were exchanged, compared to its average volume of 117,085. The company has a current ratio of 5.35, a quick ratio of 5.35 and a debt-to-equity ratio of 0.02. Diffusion Pharmaceuticals has a fifty-two week low of $1.83 and a fifty-two week high of $11.00. The firm has a market cap of $7.33 million, a P/E ratio of -0.35 and a beta of -0.04. The firm has a 50-day simple moving average of $2.44.
Separately, ValuEngine upgraded shares of Diffusion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.
See Also: Discount Rate
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.